Last checked at 
Verici Dx PLC - Cardiff-based kidney transplant test developer - Announces partnership with New York-listed biotechnology firm Illumina Inc, to expedite the launch of the predictive artificial intelligence component of Verici's products.
The company's products will have early access to Illumina's new software platform, Illumina Connected Analytics, which is used for operationalised secondary analysis with an advanced data science environment.
The platform will provide Verici Dx with the ability to process large datasets, allowing AI-enabled RNA signature testing to be more widely available.
"We are delighted to announce the successful operational launch of the Verici Dx data analysis processing and predictive artificial intelligence components of our clinical products as inaugural users of Illumina's new ICA platform. Our leading-edge science depends on the ability to process vast amounts of data into meaningful and interpretable segments, and we believe there is no better tool to support us in this than ICA," said Chief Executive Officer Sara Barrington.
Current stock price: 54.40 pence, down 4.6% on Wednesday
12-month change: down 6.2%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.